

Amendments to the Claims

The listing of claims below is intended to replace all prior listings of claims presented in the above-identified application.

1. (Currently amended) A method of treating Alzheimer's Disease in a subject comprising:

administering to the subject an agent, wherein the agent (1) ~~binds to a site of apolipoprotein E that binds to SEQ ID NO:4~~ is a protein comprising an amino acid sequence of at least 5 of the amino acids, in sequence, of SEQ ID NO:3, the protein including residue 18 of SEQ ID NO:3 and having an amino acid substitution of the valine at residue 18 which renders the protein non-fibrillogenic, and (2) inhibits interaction between amyloid- β peptide and apolipoprotein E, compared to when the agent is absent, to treat Alzheimer's Disease in the subject.

2-4 (Canceled)

5. (Currently amended) The method according to ~~claim 4~~ claim 1, wherein the ~~agent is a protein comprising~~ agent comprises an amino acid sequence of ~~SEQ ID NOs: 3 or 4~~ SEQ ID NO:4.

6-7 (Canceled)

8. (Currently amended) The method according to claim 1, wherein the ~~agent is a protein comprising an amino acid sequence of SEQ ID NOs: 3 or 4, wherein the protein~~ is prepared with D-amino acids, an amidated C-terminus, or an acetylated N-terminus.

9. (Original) The method according to claim 1, wherein said administering is carried out orally, intradermally, intramuscularly, intraperitoneally, intravenously, subcutaneously, or intranasally.

10-11 (Canceled)

12. (Currently amended) A method of inhibiting accumulation of amyloid- β peptide deposits in a subject's brain comprising:

administering to the subject an agent, wherein the agent (1) ~~binds to a site of apolipoprotein E that binds to SEQ ID NO:4~~ is a protein comprising an amino acid sequence of at least 5 of the amino acids, in sequence, of SEQ ID NO:3, the protein including residue 18 of SEQ ID NO:3 and having an amino acid substitution of the valine at residue 18 which renders the protein non-fibrillogenic, and (2) inhibits interaction between amyloid- β peptide and apolipoprotein E, compared to when the agent is absent, to inhibit accumulation of amyloid- β peptide deposits in the subject's brain.

13-18 (Canceled)

19. (Currently amended) The method according to claim 12, wherein the ~~agent is a protein comprising an amino acid sequence of SEQ ID NOs: 3 or 4, wherein the protein~~ is prepared with D-amino acids, an amidated C-terminus, or an acetylated N-terminus.

20. (Original) The method according to claim 12, wherein said administering is carried out orally, intradermally, intramuscularly, intraperitoneally, intravenously, subcutaneously, or intranasally.

21-26. (Canceled)

27. (New) The method according to claim 12, wherein the protein comprises an amino acid sequence of SEQ ID NO:4.